- Home
- OCUL vs WGS Comparison
OCUL vs WGS Comparison
Compare OCUL & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- WGS
- Stock Information
- Founded
- OCUL 2006
- WGS 2017
- Country
- OCUL United States
- WGS United States
- Employees
- OCUL N/A
- WGS N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- OCUL Health Care
- WGS Technology
- Exchange
- OCUL Nasdaq
- WGS Nasdaq
- Market Cap
- OCUL 2.3B
- WGS 2.4B
- IPO Year
- OCUL 2014
- WGS N/A
- Fundamental
- Price
- OCUL $12.17
- WGS $127.92
- Analyst Decision
- OCUL Strong Buy
- WGS Strong Buy
- Analyst Count
- OCUL 7
- WGS 7
- Target Price
- OCUL $17.83
- WGS $102.14
- AVG Volume (30 Days)
- OCUL 2.2M
- WGS 558.5K
- Earning Date
- OCUL 11-13-2025
- WGS 10-28-2025
- Dividend Yield
- OCUL N/A
- WGS N/A
- EPS Growth
- OCUL N/A
- WGS N/A
- EPS
- OCUL N/A
- WGS 0.05
- Revenue
- OCUL $56,664,000.00
- WGS $362,321,000.00
- Revenue This Year
- OCUL N/A
- WGS $35.84
- Revenue Next Year
- OCUL $18.87
- WGS $18.46
- P/E Ratio
- OCUL N/A
- WGS $2,638.92
- Revenue Growth
- OCUL N/A
- WGS 48.70
- 52 Week Low
- OCUL $5.79
- WGS $35.88
- 52 Week High
- OCUL $13.85
- WGS $136.00
- Technical
- Relative Strength Index (RSI)
- OCUL 46.53
- WGS 59.36
- Support Level
- OCUL $12.27
- WGS $118.27
- Resistance Level
- OCUL $13.07
- WGS $129.25
- Average True Range (ATR)
- OCUL 0.62
- WGS 5.47
- MACD
- OCUL -0.10
- WGS -1.72
- Stochastic Oscillator
- OCUL 7.92
- WGS 54.43
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.